'Gastric bypass pill' causes weight loss with no side effects: Study
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study) Additional Rybelsus® and Ozempic® data demonstrate new cardiometabolic benefits (improvements in heart and metabolic health) in people living with type 2 diabetes (SOUL and STRIDE studies) New insights into the role of inflammation in cardiovascular disease on mortality and major cardiovascular events in people living with inflammation in the heart vessels Bagsværd, Denmark, 20 August 2025 – Novo Nordisk today announced new data showing the cardiovascular protective benefits of Wegovy® and Ozempic® will be presented at the European Society of Cardiology (ESC) Congress 2025 from 29 August to 1 September in Madrid, Spain. New data will also include perspectives on the role of inflammation in a condition called atherosclerotic cardiovascular disease (ASCVD). 'For people living with diabetes and obesity, heart disease is one of the biggest threats that could change a person's life in an instant. Semaglutide is proven to reduce the risk of cardiovascular events by 20-26%1, meaning fewer hospitalisations, heart attacks, stroke and deaths,' said Ludovic Helfgott, executive vice president and head of Product & Portfolio Strategy at Novo Nordisk. The key role of cardiovascular inflammation in ASCVD will be discussed in a Novo Nordisk symposium on Saturday, 30 August. ASCVD is a condition where blood vessels that carry blood to your heart cut off the blood flow to other parts of your body, making those vessels stiff and narrow. Additionally, a range of real-world evidence is being presented, providing a thorough analysis of the impact of inflammation in cardiovascular disease on mortality and major cardiovascular events in people with ASCVD. Real-world evidence is data from everyday healthcare settings that show how treatments work in real life, beyond controlled clinical trials. 'At the ESC congress, we are presenting new data substantiating the unique range of benefits semaglutide has on people with heart and kidney disease, as demonstrated in both clinical trials and in the real world,' Ludovic Helfgott said. 'Semaglutide is unrivalled in the GLP-1 class with its proven reduction in heart attack, stroke, kidney complications and cardiovascular death.' Key Novo Nordisk data at the ESC congress 2025 include: Scientific Sessions: Unravelling cardiovascular inflammation in atherosclerotic cardiovascular disease (ASCVD): from evidence to guidance – Saturday 30 August; 10:00 – 10:45 CEST GLP-1RAs in obesity-related HFpEF: a new era in treatment – Sunday 31 August; 10:00 –10:45 CEST A change of heart – why cardiologists can't ignore semaglutide – Sunday 31 August; 12:30 – 13:30 CEST Poster and oral presentations:Ozempic® (once-weekly semaglutide 1.0 mg) Effect of semaglutide in patients with type 2 diabetes and peripheral artery disease: an analysis of the STRIDE trial stratified by disease severity and age – Friday 29 August; 08:35 – 08:45 CEST STRIDE Outcomes by Sex – Sunday 31 August; 09:15 – 09:30 CEST Rybelsus® (once-daily oral semaglutide) Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial – Friday 29 August; 14:40 – 14:50 CEST Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis – Saturday 30 August; 08:33 – 08:51 CEST Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes – Monday 1 September; 13:15 – 14:00 CEST Wegovy® (once-weekly semaglutide 2.4 mg) Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial – Friday 29 August; 14:30 – 14:40 CEST Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice – Sunday 31 August; 09:00 – 09:15 CEST Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial – Sunday 31 August; 17:40 – 17:50 CEST Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial – Monday 1 September; 13:15 – 14:00 CEST Cardiovascular inflammation Associations between C-reactive protein levels and mortality in individuals with atherosclerotic cardiovascular disease and chronic kidney disease: results from the UK Discover database – Friday 29 August; 08:51 – 09:09 CEST Residual inflammation, cholesterol risks and rates of major cardiovascular events in routinely cared patients with atherosclerotic cardiovascular disease – Sunday 31 August; 08:45 – 08:55 CEST Direct healthcare costs for individuals with atherosclerotic cardiovascular disease, chronic kidney disease stages 3–4 or both: results from the UK Discover database – Monday 1 September; 14:15 – 15:00 CEST Awareness and perceptions on the role of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: a national study among cardiologists and nephrologists in China – Monday 1 September; 14:15 – 15:00 CEST General obesity Cardiovascular outcomes in a SELECT-like obesity population: real-world insights from the Swedish AROS study – Saturday 30 August; 10:15 – 11:00 CEST If you have any questions about the data or want more information, reach out to globalmedia@ About semaglutideSemaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that mimics the effects of the naturally occurring hormone GLP-1. It has been tested in several robust clinical development programmes and outcomes studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases1-8. Semaglutide is marketed under the brand names Wegovy® (once-weekly semaglutide 2.4 mg injection), Ozempic® (once-weekly semaglutide 1.0 mg injection), and Rybelsus® (once-daily oral semaglutide 14 mg)6-8. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Christoffer Sho Togo Tullin+45 3079 1471cftu@ Alex Bruce +45 34 44 26 13axeu@ Frederik Taylor Pitter +1 609 613 0568fptr@ _______________________References1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-1844.2. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109-121.3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232.4. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275-286.5. McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392:2001-2012.6. Ozempic® (once-weekly semaglutide): Summary of Product Characteristics. Available at: Last accessed: August 2025.7. Wegovy® (semaglutide injection 2.4 mg): Summary of Product Characteristics. Available at: Last accessed: August 2025.8. Rybelsus® (once-daily oral semaglutide): Summary of Product Characteristics. Available at: Last accessed: August 2025. Attachment PR250820-Curtain-Raiser-ESC-2025
Yahoo
7 hours ago
- Yahoo
1 Reason to Buy NVO
Key Points It is clearly very effective at developing drugs. Its Wegovy recently earned FDA approval for a new indication. 10 stocks we like better than Novo Nordisk › It's one thing for a pharmaceutical company to have a blockbuster drug in its portfolio. It's quite another if such a product can be successfully extended to win approvals for other indications. This is one huge reason to believe in the future of Novo Nordisk (NYSE: NVO), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in its cap with the product, and it feels as if it has far more distance to go with drug discovery. Wegovy has legs In mid-August the company hit paydirt when the U.S. Food and Drug Administration (FDA) approved it as a treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adult patients with moderate to advanced liver fibrosis. The drug is intended to be used in combination with an increase in physical activity, and a reduction in caloric food intake. It probably goes without saying that America's obesity problem affects far more individuals than does MASH. But Novo Nordisk's successful development of the drug to treat the liver disorder demonstrates two very positive things; 1) Wegovy (and by extension its sibling medication, Ozempic) has the potential to treat numerous other afflictions and, 2) generally, the company is adept at developing its molecules for a variety of indications. Pipeline to greater success? Novo Nordisk has quite the impressively wide pipeline, and semaglutide (the molecule which is the primary ingredient of Wegovy and Ozempic) is only one part of it. It's in the later stages of investigating the drug for treatment of Alzheimer's; meanwhile, it's got a host of other molecules in programs aimed in many therapeutic directions. With such a high pitch of activity, the future is bright for semaglutide and other investigational drugs. And, by extension, their developer. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Reason to Buy NVO was originally published by The Motley Fool
Newsweek
9 hours ago
- Newsweek
Californians Warned of 'Devastating' New Health Insurance Costs
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Health insurance costs are set to increase for Californians in 2026, and the state's health insurance marketplace has warned that the impacts could be a major burden on American families. This comes as health insurance premiums are expected to rise significantly across the country next year, when enhanced tax credits are set to expire, as President Donald Trump has not chosen to renew them. A spokesperson for Covered California told Newsweek: "The combined impact of the premium increases and the loss of enhanced premium tax credits would be devastating for Californians." "All Covered California enrollees would face higher costs, and the loss of enhanced tax credits alone could result in an average net premium increase of 66 percent for 1.7 million enrollees," they said. The spokesperson called it "a catastrophic financial burden for many, potentially pricing a significant number of individuals and families out of coverage." "Those with the lowest incomes would be hit hardest, as stagnant wages and rising inflation amplify their challenges." Why It Matters Aside from the expiration of enhanced tax credits, which will see 2026's rise in costs jump much higher than previous years, there are also a number of other factors pushing up premiums. These factors include increased health care costs, inflation, labor costs, and rising demand for medications such as GLP-1 drugs like Ozempic and Wegovy, which are driving up prescription drug spending. While premiums have been steadily increasing over the years, 2026 will see the largest hike in prices since 2018, according to KFF data. Agents help sign people up for insurance through the Covered California exchange at their storefront in Huntington Beach, California. Agents help sign people up for insurance through the Covered California exchange at their storefront in Huntington Beach, California. Nick Agro/The Orange County Register via AP What To Know Covered California recently announced that it would be increasing rates for health coverage in 2026 by an average of 10.3 percent across various health plans. Those on Affordable Care Act (ACA)-compliant plans will be affected, as the temporary subsidies for ACA marketplaces, introduced by former President Joe Biden to increase access to health coverage, will expire at the end of 2025. While there is still time for the Trump administration to opt to extend the subsidies, there has been no indication yet by the administration that they intend to, and the subsidies also come at a significant cost to the taxpayer. Covered California told Newsweek that its planned 10.3 percent increase is lower than the national average of 20 percent, with states like Florida having much higher proposed increases. The reason for the state marketplace's increase in premium costs is driven by several factors, the Covered California spokesperson told Newsweek, pointing to "rising health care and pharmacy costs, as well as broader industry challenges." They said that federal health care policies were also "contributing to these increases, particularly the expiration of federal enhanced premium tax credits at the end of 2025." "These credits have helped millions of Americans lower their premiums since 2021, and their expiration will have significant consequences for affordability nationwide," they said. The state marketplace previously said that Congress could reduce these price hikes for Americans by extending the enhanced tax credits, and that it hoped lawmakers on both sides of the aisle "recognize the need to extend this essential lifeline for working families." What People Are Saying A spokesperson for Covered California told Newsweek: "To mitigate these impacts, California is taking proactive steps to shield its lowest-income enrollees from steep increases. For 2026, the state has allocated $190 million from its cost-sharing reduction program to provide state subsidies for individuals earning up to 150 percent of the federal poverty level, helping keep premiums comparable to 2025 levels. "This assistance will benefit individuals with annual incomes of $23,475 or less and families of four earning up to $48,225. Additional support will also be available to those earning up to 165 percent of the federal poverty level." Jonathan Gruber, a professor of economics at Massachusetts Institute of Technology, told Newsweek: "Rates are certainly going to go up because of two changes: the [One Big Beautiful Bill] kicks some folks off exchanges and makes it harder for others to enroll and the additional subsidies that President Biden added to the exchanges are going to expire. When these changes happen it is the healthiest folks who will drop out of the exchanges, raising premiums for everyone else." He added, "This is disastrous for both economic security and health. Studies have shown that losing insurance is associated with enormous economic risk and worse health, including death." Ge Bai, a professor of health policy and management at Johns Hopkins Bloomberg School of Public Health, Maryland, told Newsweek: "ACA-compliant plans have always been expensive, but the federal government has made them appear affordable through taxpayer subsidies. The premiums we see now reflect their actual unaffordability, rather than the artificial affordability created by subsidies." She said: "While market characteristics may cause some state-to-state variations, the overall trend will be upward everywhere because the regulatory constraints driving up costs apply to ACA-compliant plans in all states." "ACA-compliant plans will become more expensive, especially for higher-income beneficiaries who lose subsidy eligibility. We urgently need to address the ACA's regulatory constraints that block affordable plans, rather than pouring taxpayer dollars into creating the illusion of affordability and worsening these plans' true unaffordability." What Happens Next The proposed increases are for the 2026 calendar year, and many are concerned about the impacts they will have on Americans.
